Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Nisin in Oral Cavity Squamous Cell Carcinoma (OCSCC) — Stella

Home/Oral Cavity Squamous Cell Carcinoma/Nisin in Oral Cavity Squamous Cell Carcinoma (OCSCC)

View on ClinicalTrials.gov

Recruiting

Back to Oral Cavity Squamous Cell Carcinoma trials

Nisin in Oral Cavity Squamous Cell Carcinoma (OCSCC)

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

United States

University of California, San Francisco, San Francisco, California

Key details

Phase

Early testing / Safety & dosing

Sponsor

University of California, San Francisco

Collaborators

University of California, Los Angeles, National Cancer Institute (NCI)

Enrollment target

~40 participants

Started

February 2024

Primary completion

March 2028

Age range

18 Years and older

Last updated April 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.